Eusaprim

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eusaprim

Eusaprim is a prescription-only, synthetic antimicrobial agent known generically as co-trimoxazole or TMP-SMX, officially recognized as a fixed-dose combination product containing two active substances. This medicine is a broad-spectrum antibiotic used to resolve various infections by stopping the growth and division of susceptible bacteria.


Quick Facts

Property Description
Active ingredient Sulphamethoxazole and Trimethoprim
Form Tablet, oral suspension, intravenous solution
Pharmacological class Sulfonamide and Antifolate Antibiotic
Common use Fighting bacterial infections
Origin Synthetic combination product

Classification and Identity of the Combination Antibiotic

Eusaprim is a synthetic antibacterial combination product belonging to the sulfonamide antibiotic class, available in forms such as tablets, oral suspension, and solutions for intravenous administration. Its identity lies in being a dual-action therapeutic agent, a feature clinically recognized for its reliable efficacy against a wide spectrum of bacteria. The drug is administered via the oral or intravenous route depending on the formulation. This composition ensures a more effective approach to clearing infections compared to using either substance alone, which is a key distinguishing feature of co-trimoxazole.


What are the Active Ingredients in Co-trimoxazole?

The active ingredients in Eusaprim are a precise fixed ratio of Sulphamethoxazole and Trimethoprim, both of which are synthetic compounds. Sulphamethoxazole is the sulfonamide component, and Trimethoprim is an antifolate agent, creating a synergistic pairing. This particular two-drug combination is designed to work together to deliver a decisive blockade of microbial growth. This synergistic mechanism effectively inhibits the synthesis of tetrahydrofolic acid in susceptible bacteria. This action enables the body's immune system to eliminate the microbial population and resolve the infection.


General Purpose of Eusaprim

The general purpose of Eusaprim is to act as an effective anti-infective agent by interfering with the ability of susceptible bacteria to survive and multiply. The medicine uses its synergistic anti-folate mechanism to deliver a decisive blockade of microbial growth. This action ultimately benefits the patient by efficiently halting the proliferation of pathogenic microorganisms, which is essential for alleviating the symptoms and severity associated with uncontrolled bacterial overgrowth in the body.

Regulatory References

  1. Co-trimoxazole Mechanism of Action
  2. NLM Drug Information

What side effects are possible with Eusaprim?

Possible side effects and safety information

The safety profile for Eusaprim (co-trimoxazole) is formally classified by regulatory authorities, encompassing adverse reactions across multiple physiological systems. The official classification identifies Hyperkalaemia (elevated serum potassium) as a Very Common effect, reflecting its potential impact on metabolic balance. Other common adverse reactions documented in regulatory labeling include headache, nausea, diarrhea, and rash.


System-Organ Classes and Serious Reactions

Adverse effects are formally categorized by System-Organ Classes, including Blood and Lymphatic System Disorders, Skin and Subcutaneous Tissue Disorders, and Renal and Urinary Disorders. The official label highlights the risk of Serious Adverse Reactions that are rare but clinically significant. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and life-threatening blood dyscrasias, such as Aplastic Anaemia and Agranulocytosis.


Population-Specific Safety Notes

The regulatory profile specifies increased safety considerations for certain groups. Older adults are officially documented as having an increased susceptibility to severe adverse reactions, particularly with concurrent renal or hepatic impairment. The medicine is contraindicated in infants less than two months of age due to the risk of hyperbilirubinaemia. Additionally, the highest risk for developing SCARs is officially noted to occur within the first few weeks of treatment.


Safety-Related Restrictions: The medicine is contraindicated in patients with officially diagnosed severe hepatic damage or severe renal impairment where plasma concentrations cannot be monitored, or in cases of documented megaloblastic anaemia due to folate deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Eusaprim (co-trimoxazole) strictly defines the manifestations of overdosage and the required emergency procedures. Acute overexposure may initially present with non-specific gastrointestinal and neurological symptoms, including Nausea, Vomiting, Confusion, Headache, and Drowsiness. Chronic overdosage can lead to Bone Marrow Depression and subsequent Megaloblastic Anaemia.

Severe Manifestations and Emergency Action

Regulators emphasize the critical risk of life-threatening systemic outcomes. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), Fulminant Hepatic Necrosis, Acute Respiratory Distress Syndrome (ARDS), and serious Blood Dyscrasias. Individuals must seek immediate medical attention when signs of these severe events occur, such as a progressive skin rash (especially with blistering), fever, or difficulty breathing. The medicine must be discontinued immediately upon the first appearance of any life-threatening symptoms.

Supportive Management

Management consists of symptomatic and supportive treatment, as no specific antidote is known. Documented procedural steps include maintaining adequate urinary output to reduce the risk of crystalluria and monitoring the total plasma concentration of sulfamethoxazole to guide clinical interruption. Regulatory documents note that elderly patients and those with severe renal impairment have an increased susceptibility to toxicity.

Therapeutic Uses of Eusaprim

Quick Facts

  • May help manage: Urinary tract infections, acute flare-ups of chronic bronchitis, and acute ear infections.
  • Is an option for: Treating certain enteric infections, including shigellosis and traveler's diarrhea.
  • Approved for: Addressing Pneumocystis pneumonia (PCP), a specific type of lung infection, for both treatment and prevention.

Eusaprim (a combination of sulfamethoxazole and trimethoprim) is approved for managing a variety of bacterial infections. It may be prescribed to address acute infective exacerbations of chronic bronchitis, which may help reduce the duration and severity of symptoms. The medication is used for treating and preventing Pneumocystis pneumonia (PCP), which is a specific lung infection.

This medication is an option for treating certain bacterial urinary tract infections (UTIs) in adults and children over two months of age. It may also be utilized to manage particular cases of acute otitis media (ear infections) and certain enteric infections, such as those caused by susceptible strains of Shigella and E. coli that cause traveler’s diarrhea. Consult a healthcare professional for appropriate usage and to learn more about the approved indications.

Eligibility and Restrictions for Use

Official Contraindications and Exclusions

Eusaprim (co-trimoxazole) is strictly contraindicated and must not be used by several groups, as specified in regulatory labeling. Absolute non-eligibility includes patients with a known hypersensitivity to trimethoprim or sulfonamides, as well as those with documented megaloblastic anemia due to folate deficiency. The medicine is also prohibited for patients with marked hepatic damage or severe renal insufficiency when kidney function cannot be closely monitored. Use is contraindicated in infants less than 2 months of age. Due to potential risks, the medicine must not be used during pregnancy or by nursing mothers. Use is also prohibited if the patient has a history of drug-induced immune thrombocytopenia or is taking dofetilide.

Approved Populations and Conditional Eligibility

The medicine is approved for children 2 months of age and older and adults. For other populations, use is conditional and requires caution. Patients with impaired renal function (e.g., Creatinine Clearance 15–30 mL/min) are eligible but require dosage reduction and close medical supervision. Caution is advised for older adults due to a higher susceptibility to adverse reactions and for patients with G6PD deficiency due to the risk of hemolytic anemia. Patients with HIV/AIDS may also experience a higher incidence of adverse events, necessitating careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eusaprim (co-trimoxazole) may interact with a wide range of medicinal products, potentially altering their effects or increasing the risk of adverse reactions. These interactions are documented in regulatory labeling and are classified based on the mechanism and resulting clinical impact.


Contraindicated Combinations

Certain combinations are not permitted due to high risks. These include co-administration with Dofetilide and Clozapine.

Pharmacokinetic and Exposure Modification

Eusaprim can affect the blood concentration of several drugs. The elimination of highly protein-bound drugs such as Warfarin and Phenytoin may be inhibited, potentially increasing their exposure. Co-trimoxazole also increases the plasma levels of Digoxin and the antidiabetic agent Repaglinide, requiring careful monitoring.

Pharmacodynamic and Additive Effects

Combination with other anti-folate agents like Methotrexate or high-dose Pyrimethamine can lead to an additive risk of haematological suppression. Concomitant use with ACE inhibitors, ARBs, or potassium-sparing diuretics raises the risk of hyperkalemia (high potassium levels). Additionally, the trimethoprim component interferes with the renal tubular secretion of creatinine, leading to a non-pathological increase in serum creatinine readings.

Population-Specific Notes

Increased risk of thrombocytopenia is noted when Eusaprim is used concurrently with thiazide diuretics in elderly patients. Specific considerations are also required for the interaction with Ciclosporin in renal transplant patients.

Mechanism of Action

Targeting the Bacterial Folate Synthesis Pathway

Eusaprim functions by sequentially inhibiting two enzymatic steps in the bacterial pathway required for synthesizing essential tetrahydrofolic acid (THF). The combination of Sulphamethoxazole and Trimethoprim involves dual action: Sulphamethoxazole inhibits the enzyme Dihydropteroate Synthase (DHPS), and Trimethoprim blocks the subsequent action of Dihydrofolate Reductase (DHFR). This dual intervention leads to the depletion of the THF cofactor required for microbial growth.

The Mechanism of Synergistic Metabolic Blockade

The combination of the two inhibitors produces a synergistic effect; their combined action is disproportionately stronger than the effect of either substance alone. This sequential, double blockade prevents the formation of new DNA and RNA precursors and essential proteins, causing a rapid cessation of proliferation and a shift toward a bactericidal (killing) action. This profound inhibition rapidly limits the microbial population and reduces the proliferative threat.

Selective Action Based on Cellular Need

The mechanism is characterized by selective toxicity due to its targeted action on de novo folate synthesis, a metabolic function essential for susceptible bacteria. Mammalian cells, unlike bacteria, obtain their necessary folate from the diet and thus do not rely on the drug-sensitive pathway for survival. This selectivity ensures the mechanism acts primarily upon the microbial population.

Dosage and Administration Information

Official Administration Guidelines for Eusaprim (Co-trimoxazole)

Eusaprim (co-trimoxazole) is used according to specific instructions for dosing and administration detailed in prescribing information, which define its proper use.


Approved Routes and Standard Dosing

Administration Route Standard Adult Dose (DS Tablet) Frequency Pattern
Oral (Tablet, Suspension) 800 mg SMX / 160 mg TMP (Double-Strength) Typically every 12 hours (twice daily)
Intravenous (IV) Infusion Weight-based for severe infections (e.g., 15 to 20 mg TMP/kg/day) Every 6 to 8 hours (3–4 times daily)

The oral form is the primary route, while the intravenous form is generally reserved for severe infections or when oral intake is not possible. The medicine is not recommended for children under two months of age. Pediatric doses are calculated based on the child's body weight (mg/kg).


Use Conditions and Duration

  • Fluid Intake: Patients are instructed to take the oral dose with a full glass of water and maintain adequate fluid intake throughout the course of therapy.
  • Timing: The medicine may be taken with or without food.
  • IV Preparation: The concentrate for injection must be diluted in a compatible fluid (e.g., 5% Dextrose in Water) prior to administration and must be infused slowly over a period of 60 to 90 minutes. Rapid injection is prohibited.
  • Treatment Length: The duration of use is fixed by the treatment plan, typically ranging from 5 days (e.g., shigellosis) to 14 or 21 days (e.g., severe infections).

Renal Impairment Adjustment

Dosage modification is required for patients with reduced kidney function. For adults with a Creatinine Clearance (CrCl) of 15 to 30 mL/min, the dose is officially reduced to half of the standard regimen. Use is generally not recommended when CrCl is below 15 mL/min.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eusaprim

This overview describes the types of clinical research conducted for Eusaprim and what the scientific literature indicates remains uncertain. The information reflects findings from governmental and peer-reviewed sources.

Research Investigating Urinary Tract Infections (UTIs)

Research has explored its use in certain bacterial Urinary Tract Infections (UTIs). Short-term Randomized Controlled Trials (RCTs) monitored a composite outcome that included patient-reported discomfort (symptom resolution) and laboratory measurements of bacterial clearance. The research focused on adults and children over two months of age. The evidence quality varies across studies, and this inconsistency may indicate that historical findings are not always comparable to more recent analyses.

Research Investigating Pneumocystis Pneumonia (PCP)

Research investigated outcomes related to systemic imbalance associated with Pneumocystis Pneumonia (PCP) in immunocompromised individuals. Systematic Reviews and Meta-analyses examined treatment and prevention strategies (prophylaxis), monitoring mortality rates and the rate of new PCP occurrences. Research highlights patterns where the preventive regimen was associated with a reduced incidence of the infection. However, long-term effects are not fully established for all immunocompromised groups, and data for optimizing dosage in non-HIV populations are still emerging.

Acute Bronchitis, Enteric Infections, and Research Gaps

Eusaprim was studied for acute exacerbations of chronic bronchitis (AECB), where RCTs monitored symptom change and time until the next acute episode. Studies reported mixed findings when monitoring for relapse. For enteric infections, clinical trials described short-term symptom patterns, but data show patterns of high and rising prevalence of drug resistance in the causative bacteria. Follow-up durations were limited in many acute infection studies, meaning there is limited information for long-term outcomes. Data for certain groups, such as non-ambulatory older adults, remain insufficient. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. SULFAMETHOXAZOLE AND TRIMETHOPRIM tablet official label information (FDA-approved product monograph).
  2. Co-trimoxazole: Drug Information (National Library of Medicine).

Frequently Asked Questions (FAQ)

Common questions about Eusaprim (FAQ)


Q: How quickly does Eusaprim start working after I take it?

The official product information describes Eusaprim's mechanism as rapidly halting the growth of susceptible bacteria. Studies indicate that the drug's active ingredients begin to enter the bloodstream and take effect relatively quickly, often within one to two hours. However, seeing an improvement in symptoms or infection may still require a few days of consistent use.


Q: What is the difference between Eusaprim and other common antibiotics?

Eusaprim is a combination antimicrobial, distinct from many single-agent antibiotics. It contains Sulphamethoxazole and Trimethoprim, which work together to create a synergistic blockade—meaning their combined action is much stronger than if they were used alone. This dual action targets the bacterial pathway for producing essential substances, differentiating its mechanism from classes like penicillin, which target the cell wall.


Q: Does Eusaprim treat bacterial infections only, or other types as well?

According to official regulatory documents, Eusaprim is primarily used to resolve infections caused by susceptible bacteria. However, it is also specifically indicated for the treatment and prevention of Pneumocystis jirovecii pneumonia (PJP). This indicates that the medicine is used for conditions beyond strictly bacterial pathogens.


Q: What should I do if I miss a dose of Eusaprim?

Regulatory guidance suggests taking the dose as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, regulatory guidance suggests skipping the missed dose and continuing with the regular treatment schedule. Patients are cautioned against taking a double dose to compensate for the one that was missed.


Q: Is it normal to feel tired when taking Eusaprim?

Fatigue or unusual tiredness is listed among the possible adverse effects in the official safety information for Eusaprim. If persistent or severe tiredness is noted while taking this medicine, reporting it to a healthcare provider is recommended.


Q: Does Eusaprim affect blood sugar levels?

Official safety information indicates that Eusaprim may potentially cause hypoglycemia (low blood sugar) in certain patients. This effect is seen more commonly in individuals who have pre-existing risk factors, such as kidney or liver impairment.


Q: What foods or drinks should be avoided while on Eusaprim?

No specific foods are officially prohibited because they would stop the medication from working. However, Eusaprim is known to increase potassium levels in the blood, a condition called hyperkalemia. Official documents note the importance of consulting with a healthcare provider regarding the management of potassium intake.


Q: Is it safe to drink alcohol in moderation while taking Eusaprim?

The combination of Eusaprim and alcohol is generally discouraged by health authorities. Using this medicine concurrently with alcohol may increase the risk of experiencing adverse side effects. These reactions can include physical symptoms such as nausea, vomiting, facial flushing, and fast heartbeats.


Q: Are there different strengths of Eusaprim available?

Yes, official regulatory documents confirm that Eusaprim is available in different strengths, as well as multiple dosage forms (like oral suspension and IV solution). Common oral forms include the single-strength and double-strength tablets, each containing a fixed ratio of Sulphamethoxazole (SMX) and Trimethoprim (TMP).


Q: Does Eusaprim make you more sensitive to the sun?

Official product information indicates that Eusaprim may cause photosensitivity, meaning your skin may become more sensitive to sunlight or ultraviolet (UV) light. To minimize risk, official information recommends precautions, such as using sunscreen and protective clothing, during periods of sun exposure.


Q: How long after finishing Eusaprim can I stop avoiding the sun?

Sun sensitivity (photosensitivity) may occur while actively taking Eusaprim, and in some cases, it can persist for a period of weeks after the medicine has been discontinued. Official guidance emphasizes the importance of clinical consultation for specific advice on sun exposure following the completion of therapy.


Q: Are there specific tests needed before starting Eusaprim?

Because Eusaprim has the potential to affect blood cell counts and kidney function, official clinical guidelines often require specific laboratory monitoring. A full blood count (FBC) and kidney function tests, such as creatinine clearance, may be performed both before starting treatment and periodically throughout the course of therapy.


Q: Does Eusaprim interact with common pain relievers like ibuprofen?

Official interaction summaries focus on major drug-to-drug interactions. While common over-the-counter pain relievers like ibuprofen (an NSAID) may not be listed as a strictly contraindicated combination, regulatory information advises caution when mixing medications. Consultation with a healthcare provider is noted for guidance on co-administering any medications.


Q: Can Eusaprim cause joint pain?

Yes, joint pain is listed in the official safety documents as a possible side effect of Eusaprim. If you experience discomfort in your joints while taking this medicine, you should mention it to your healthcare provider.


Q: Can Eusaprim cause dizziness or affect driving?

Dizziness is listed in the official product information as a possible side effect of Eusaprim. If a patient experiences these effects, using caution when performing activities that require alertness, such as driving or operating heavy machinery, is appropriate.


Q: Can Eusaprim be crushed or split if swallowing is difficult?

If a tablet formulation of Eusaprim has a scoreline, regulatory information indicates that this line is typically present to facilitate breaking the tablet for ease of swallowing. The scoreline is primarily intended to aid in swallowing the full tablet, and regulatory information does not support its use for creating separate, equally divided doses.


Q: Does Eusaprim cause changes in mood or confusion?

Official safety reports list confusion as a possible adverse effect associated with Eusaprim. This neurological symptom is sometimes seen when the medicine causes changes in metabolic balance, such as low blood sugar or an imbalance of electrolytes (like sodium).


Q: Does Eusaprim lose effectiveness over time if used repeatedly?

Studies and regulatory reviews note that the widespread or improper use of any antibiotic, including Eusaprim, contributes to the overall rise in bacterial resistance. This means that over time, the drug may become less effective against the specific strains of bacteria that cause certain infections.


Q: What is the evidence supporting the use of Eusaprim for traveler's diarrhea?

Regulatory documents specifically include Traveler's Diarrhea in adults as an approved indication for Eusaprim (co-trimoxazole). This use is based on its efficacy against susceptible strains of bacteria, particularly Escherichia coli, which is a common cause of this condition.


Q: Is there a link between Eusaprim and kidney stones?

Regulatory information notes that the sulfonamide component of Eusaprim can potentially form crystals in the urine. This crystal formation can sometimes lead to kidney injury or, in rare instances, the development of kidney stones. Official product information suggests that maintaining adequate fluid intake throughout therapy can help minimize this risk.


Q: How does Eusaprim compare to amoxicillin in terms of general use?

Eusaprim and amoxicillin belong to distinct pharmacological classes with different mechanisms of action. Eusaprim is a sulfonamide-antifolate combination that inhibits the bacterial folate synthesis pathway. Amoxicillin, by contrast, is a penicillin-class drug that works by interfering with the building of the bacterial cell wall. They are used to treat different types of bacterial infections based on the specific bacteria they are effective against.


Q: Are there specific vitamins or supplements that interact with Eusaprim?

The trimethoprim component of Eusaprim acts as an anti-folate agent. Because of this mechanism, the drug is contraindicated in patients with a specific type of anemia caused by folate deficiency. Given this mechanism, consultation with a healthcare provider regarding the intake of vitamins and supplements, particularly those containing folic acid, is relevant.


Q: Does Eusaprim have a potential for abuse or dependence?

Official regulatory documents, which include safety and scheduling information, state that Eusaprim is not classified as a controlled substance. Furthermore, there is no evidence reported in the medical literature that indicates a potential for drug abuse or dependence associated with its use.


Q: Can Eusaprim be used for long-term treatment?

While Eusaprim is often used for short-term treatment of acute infections, it is also prescribed for long-term prophylaxis, or prevention, in specific patient populations. For instance, the prevention of Pneumocystis pneumonia (PCP) can require taking the medicine over a period of several months or longer.


Q: Is Eusaprim safe for older adults (seniors)?

Eusaprim is approved for use in older adults. However, official safety documentation advises caution because this group may have an increased susceptibility to severe adverse reactions, particularly if they also have kidney or liver impairment. Specialized monitoring and dosage adjustments may be required to manage this elevated risk.


Q: How does Eusaprim affect the body's folate levels?

The active ingredient, trimethoprim, is an anti-folate agent. It works by interfering with the metabolic processes that rely on folic acid within the body. Official regulatory documents specify that because of this mechanism, the drug is contraindicated, or prohibited, in patients who already have megaloblastic anemia caused by folate deficiency.


Q: What is the difference between prophylaxis and treatment when using Eusaprim?

According to clinical and regulatory guidelines, the terms prophylaxis and treatment describe different uses of the medicine. Prophylaxis refers to taking the medicine to prevent an infection from occurring, and typically involves a low dose taken over a long duration. Treatment, conversely, refers to taking the medicine to resolve an active infection, which generally requires a higher dose for a shorter, fixed period.


Q: Why is Eusaprim not used for simple colds or the flu?

Eusaprim is an antimicrobial agent and its indicated uses are limited to susceptible bacteria and the Pneumocystis fungus. Official product information confirms that it is not effective against infections caused by viruses. Therefore, it is not used for treating viral illnesses like the common cold or seasonal influenza (the flu).


Q: What are the official warnings about Eusaprim on the drug label?

The official product label includes serious warnings about potential risks. These warnings highlight the possibilities of severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as severe blood disorders. There is also a warning concerning hyperkalemia (high potassium levels). These most critical warnings are often summarized in a dedicated Boxed Warning section.


Q: Why is Eusaprim sometimes given with a full glass of water?

Regulatory administration guidelines instruct patients to take the oral dose of Eusaprim with a full glass of water and to maintain adequate fluid intake overall. This instruction is important because it helps ensure the medicine remains diluted in the urine, which reduces the potential risk of crystals forming in the urinary tract.

How should Eusaprim be stored and disposed of?

Eusaprim (co-trimoxazole) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

Eusaprim should be kept in its original container and stored at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). The medicine must not be frozen. The oral suspension formulation specifically requires protection from light and, once opened, must be discarded after 14 days. The product must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Eusaprim must be handled as pharmaceutical waste. Do not dispose of the medicine into household wastewater (sinks or toilets). Disposal should be carried out through a local drug take-back program or by following specific instructions provided by local waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eusaprim found in:

A-Z Index: